Press Releases March 31, 2026 08:00 PM

O’Reilly Automotive, Inc. Announces Dates for Its First Quarter 2026 Earnings Release and Conference Call

O'Reilly Automotive sets dates for Q1 2026 earnings release and conference call

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
ORLY

O'Reilly Automotive, Inc., a major automotive aftermarket retailer, announced it will release its financial results for the first quarter of 2026 on April 29, 2026, followed by a conference call on April 30, 2026. The company operates over 6,500 stores across North America and serves both do-it-yourself and professional markets.

O’Reilly Automotive, Inc. Announces Dates for Its  First Quarter 2026 Earnings Release and Conference Call
ORLY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Earnings release scheduled for April 29, 2026, with a conference call on April 30, 2026.
  • O'Reilly Automotive operates 6,585 stores across 48 U.S. states, Puerto Rico, Mexico, and Canada as of end-2025.
  • The company serves both the consumer DIY and professional automotive service provider segments.
  • Earnings Release Date – Wednesday, April 29, 2026, after 3:30 p.m. Central Time
  • Conference Call Date – Thursday, April 30, 2026, at 10:00 a.m. Central Time

SPRINGFIELD, Mo., April 01, 2026 (GLOBE NEWSWIRE) -- O’Reilly Automotive, Inc. (the “Company” or “O’Reilly”) (Nasdaq: ORLY), a leading retailer in the automotive aftermarket industry, announces the release date for its first quarter 2026 results as Wednesday, April 29, 2026, with a conference call to follow on Thursday, April 30, 2026.

The Company’s first quarter 2026 results will be released after 3:30 p.m. Central Time on Wednesday, April 29, 2026, and can be viewed, at that time, on the Company’s website at www.OReillyAuto.com by clicking on “Investor Relations.”

Investors are invited to listen to the Company’s conference call discussing the financial results for the first quarter 2026, on Thursday, April 30, 2026, at 10:00 a.m. Central Time, via webcast on the Company’s website at www.OReillyAuto.com by clicking on “Investor Relations.” Interested analysts are invited to join the call. The dial-in number for the call is (888) 506-0062 and the conference call identification number is 264620. A replay of the conference call will be available on the Company’s website through April 29, 2027.

About O’Reilly Automotive, Inc.
O’Reilly Automotive, Inc. was founded in 1957 by the O’Reilly family and is one of the largest specialty retailers of automotive aftermarket parts, tools, supplies, equipment, and accessories in the United States, serving both the do-it-yourself and professional service provider markets. Visit the Company’s website at www.OReillyAuto.com for additional information about O’Reilly, including access to online shopping and current promotions, store locations, hours and services, employment opportunities, and other programs. As of December 31, 2025, the Company operated 6,585 stores across 48 U.S. states, Puerto Rico, Mexico, and Canada.

  For further information contact:Investor Relations Contacts Leslie Skorick (417) 874-7142 Eric Bird (417) 868-4259   Media Contact Sonya Cox (417) 829-5709



Risks

  • Potential impact of broader economic conditions on automotive aftermarket sales affecting company performance.
  • Uncertainty in automotive industry trends and consumer behavior which may influence demand for aftermarket parts.
  • Operational risks related to retail store management across multiple geographic locations.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026